Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.41 |
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104398 | 0.73 | HTT (0.46) | ALDH1A1ADORA3KMT2AKDM4EMAPT | |
| SCHEMBL1140881 | 0.71 | ACHE (0.41) | BCHEACHEALDH1A1ADORA3TSHR | |
| SCHEMBL2707307 | 0.71 | NSD2 (0.40) | BCHEACHEALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8121994 | 0.71 | HPGD (0.50) | BCHEACHEADORA3TSHRMEN1 | |
| SCHEMBL4794106 | 0.71 | TRPA1 (0.37) | ALDH1A1ADORA3ADORA2AADORA1TSHR | |
| SCHEMBL24287266 | 0.70 | LMNA (0.57) | BCHEACHEALDH1A1ADORA3TSHR | |
| SCHEMBL6244651 | 0.70 | ACHE (0.40) | BCHEACHEALDH1A1ADORA3TSHR | |
| SCHEMBL3818922 | 0.69 | USP2 (0.35) | SMN1; SMN2MEN1KMT2AKCNH2CYP1A2 | |
| SCHEMBL6930107 | 0.68 | ACHE (0.40) | BCHEACHEALDH1A1ADORA2ASMN1; SMN2 | |
| SCHEMBL24287389 | 0.67 | LMNA (0.57) | BCHEACHEALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-6989389-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6953804-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1341789-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | BCHE 4121/4885ACHE 4670/4885ALDH1A1 2486/4885 |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | BCHE 4586/4885ACHE 4824/4885ALDH1A1 1364/4885 |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | BCHE 4586/4885ACHE 4824/4885ALDH1A1 1364/4885 |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4028/4885ACHE 4781/4885ALDH1A1 2256/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4028/4885ACHE 4781/4885ALDH1A1 2256/4885 |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | BCHE 4586/4885ACHE 4824/4885ALDH1A1 1364/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4028/4885ACHE 4781/4885ALDH1A1 2256/4885 |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | BCHE 4586/4885ACHE 4824/4885ALDH1A1 1364/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | BCHE 4121/4885ACHE 4670/4885ALDH1A1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.